FOXO4-DRI Dosage Chart: 1mg Senolytic Protocol

FOXO4-DRI is a first-in-class senolytic peptide that selectively eliminates senescent "zombie cells" by disrupting the FOXO4-p53 interaction. Developed at Erasmus University Medical Center, it reversed aspects of aging in mice by clearing these cells from tissues. No human clinical trials exist. This is not medical advice.

Research-context information only. FOXO4-DRI is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Standard Protocol

Community-documented protocol: 1 mg subcutaneous in the morning, 5 days on / 2 days off, for 2-week courses repeated 2-3 times per year, with 3-6 months rest between courses.

Cycling: 2 Weeks On, 3-6 Months Off

Community protocols describe running 1 mg daily (5 on / 2 off) for 2 weeks, then resting 3-6 months before the next course, repeating 2-3 times per year.

The intermittent schedule reflects the "hit-and-clear" nature of senolytic therapy -- once apoptosis is triggered, the immune system needs time to phagocytose debris. Pulsed administration may also reduce off-target effects on non-senescent cells.

Enhanced Protocol (Community)

Some aggressive community protocols use weight-based dosing from the original mouse study:

The community weight-based protocol uses the direct mg/kg number from mice without allometric correction. Standard allometric scaling (BSA factor ~12.3) would suggest far lower human doses. The 1 mg community standard is the conservative entry point documented in community protocols.

Cost note: At 2-5 mg/kg for a 75 kg individual (150-375 mg per injection), FOXO4-DRI becomes one of the most expensive peptide protocols due to both the high dose and D-amino acid synthesis costs.

Routes of Administration

Subcutaneous injection (standard): At the 1 mg community-standard dose, injection volume is small (0.2 mL). At higher community doses, large volumes may require splitting across 2-3 injection sites per session.

Reconstitution Quick Reference

Math: 10 mg / 2 mL = 5 mg/mL. For 1 mg: 1 / 5 = 0.2 mL = 20 units. One vial lasts 10 doses.

FOXO4-DRI is a large peptide and can denature with aggressive agitation -- swirl very gently. May take 5-10 minutes to dissolve. Protect from light. For step-by-step instructions, see the Reconstitution Calculator.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Landmark study (Baar et al., 2017): Published in Cell, mice received 5 mg/kg IV on alternating days over ~3 weeks. Treated aged mice showed restored fur density, improved kidney function, increased fitness, and reduced senescence markers. FOXO4-DRI showed 11.73-fold selectivity for senescent over non-senescent cells in vitro.

Leydig cell aging (Zhang et al., 2020): FOXO4-DRI improved testosterone secretion in aged mice by targeting senescent Leydig cells.

Chondrocyte senescence (Zhu et al., 2021): Selectively removed senescent cells from human chondrocyte cultures, with implications for cartilage repair.

The scaling problem: Translating 5 mg/kg from mice to humans is complex. Standard allometric scaling would suggest a far lower human-equivalent dose. Community protocols using 2-5 mg/kg in humans are deliberate choices by early adopters, not FDA-guided conversions.

Ready to buy? Compare verified vendors on our best FOXO4-DRI sources page, or browse all coupon codes for up to 50% off.

Stacking Protocols

Critical: Community sources warn against combining multiple senolytics simultaneously and describe allowing adequate recovery between senolytic courses (minimum 4-6 weeks), running each compound individually first, and monitoring bloodwork (CBC, CMP, inflammatory markers) between courses.

Side Effects & Safety

• Injection site reactions -- redness, swelling, stinging (common with large-volume SC injections)
• Flu-like symptoms -- mild fever, fatigue, malaise 24-72 hours post-injection (possibly from immune clearance of apoptotic cells)
• GI discomfort -- nausea, mild digestive upset
• Temporary fatigue -- 1-3 days post-injection
• Off-target cell death (theoretical) -- no compound is perfectly selective; healthy cells with transiently elevated FOXO4 could be affected
• Immune burden (theoretical) -- rapid senescent cell clearance could overwhelm phagocytic system
• Community sources describe avoiding use with: active infection, recent surgery/wound healing, immunocompromised status, pregnancy, active cancer treatment

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once FOXO4-DRI is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.